MIDTERM MSN 610 QUESTIONS WITH
CORRECT ANSWERS 2025
HistamineWthatWisWnotWfoundWwithinWmastWcellsWfunctionsWasWaW:W-WCORRECTWANSWERW-
Neurotransmitter
ToxicWeffectsWofWfirst-generationWantihistaminesW-WCORRECTWANSWERW-cardiacWarrhythmias
WhatWclassWofWmedicationsWisWusedWasWadjustWtherapyWforWanaphylaxisW-WCORRECTWANSWERW-
steroids
centralWnervousWsystemWsideWeffectsWofWantihistaminesWthatWelderlyWpatientsWshouldWbeWawareW
ofW-WCORRECTWANSWERW-fatigue
IndicationWofWH2WantihistaminesW-WCORRECTWANSWERW-gastrointestinalWdisorders
InitialWselectionWofWantimicrobialWtherapyW-WCORRECTWANSWERW-empiric
DescribeWtheWmanagementWofWfood-drug-drugWinteractionsWwithWantibacterialWmedicationsW-
WCORRECTWANSWERW-separatingWadministrationWtimes
mechanismWofWactionWofWmultipleWdrugWcombinationWinWtheWtreatmentWofWtuberculosisW-
WCORRECTWANSWERW-
combinationWdrugWtreatmentWforWtuberculosisWhasWaWdecreasedWriskWofWresistance
DescriptionWofWINF-BW-WCORRECTWANSWERW-usedWtoWtreatWmultipleWsclerosis
typeWofWpathogenWthatWcauseWmalariaW-WCORRECTWANSWERW-protozoaWisWusedWtoWtreatWmalaria
, indicationWofWsystemicWchemotherapyWthatWtisWgivenWpriorWtoWsurgeryWorWradiationW-
WCORRECTWANSWERW-increaseWeffectivenessWofWlocalWtreatment
managementWofWtumorWlysisWsyndromeWinWleukemiaWpatientsW-WCORRECTWANSWERW-
IVWhydration
WhatWisWcausedWbyWacroleinW-WCORRECTWANSWERW-
aWtoxicWmetaboliteWofWcyclophosphamideWandWifofamideWthatWcanWcauseWhemorrhagicWcystitis
categoryWofWantineoplasticWdrugsWusedWanWalternativeWwhenWtraditionalWtreatmentsWfailW-
WCORRECTWANSWERW-
immunosuppressantsWactWasWanWalternativeWtreatmentWwhenWtraditionalWtreatmentsWfail
WhatWisWtopoisomeraseWinhibitorsWtargetWenzymesWthatWcontrolWchangesWinWDNAW-
WCORRECTWANSWERW-theyWtargetWenzymesWthatWcontrolWchangesWinWDNAWstructure
EffectsWdoWcholinesteraseWinhibitorsWhaveWonWtheWsinoatrialWandWatrioventricularWnodesW-
WCORRECTWANSWERW-VASOTONIC-
cholinesteraseWinhibitorsWhaveWeffectsWonWsinoatrialWandWatrioventricularWnodes
MechanismWofWactionWofW"mixedWacting"WsympathomimeticWdrugsW-WCORRECTWANSWERW-
theyWdirectlyWactivateWtheWreleaseWofWnorepinephrineWwhileWalsoWindirectlyWcausingWaWreleaseWo
fWnorepinephrine
IndicationWofWGABA-
derivativeWantispasmodicWagentsWinWtheWmanagementWandWcontrolWofWmuscleWspasmW-
WCORRECTWANSWERW-baclofen-
centrallyWactingWmuscleWrelaxant,WknownWtoWbeWmoreWeffectiveWwhenWusedWforWmuscularWspas
msWassociatedWwithWmultipleWsclerosisWcomparedWtoWthoseWthatWrelieveWotherWmusculoskeletalW
conditions
CORRECT ANSWERS 2025
HistamineWthatWisWnotWfoundWwithinWmastWcellsWfunctionsWasWaW:W-WCORRECTWANSWERW-
Neurotransmitter
ToxicWeffectsWofWfirst-generationWantihistaminesW-WCORRECTWANSWERW-cardiacWarrhythmias
WhatWclassWofWmedicationsWisWusedWasWadjustWtherapyWforWanaphylaxisW-WCORRECTWANSWERW-
steroids
centralWnervousWsystemWsideWeffectsWofWantihistaminesWthatWelderlyWpatientsWshouldWbeWawareW
ofW-WCORRECTWANSWERW-fatigue
IndicationWofWH2WantihistaminesW-WCORRECTWANSWERW-gastrointestinalWdisorders
InitialWselectionWofWantimicrobialWtherapyW-WCORRECTWANSWERW-empiric
DescribeWtheWmanagementWofWfood-drug-drugWinteractionsWwithWantibacterialWmedicationsW-
WCORRECTWANSWERW-separatingWadministrationWtimes
mechanismWofWactionWofWmultipleWdrugWcombinationWinWtheWtreatmentWofWtuberculosisW-
WCORRECTWANSWERW-
combinationWdrugWtreatmentWforWtuberculosisWhasWaWdecreasedWriskWofWresistance
DescriptionWofWINF-BW-WCORRECTWANSWERW-usedWtoWtreatWmultipleWsclerosis
typeWofWpathogenWthatWcauseWmalariaW-WCORRECTWANSWERW-protozoaWisWusedWtoWtreatWmalaria
, indicationWofWsystemicWchemotherapyWthatWtisWgivenWpriorWtoWsurgeryWorWradiationW-
WCORRECTWANSWERW-increaseWeffectivenessWofWlocalWtreatment
managementWofWtumorWlysisWsyndromeWinWleukemiaWpatientsW-WCORRECTWANSWERW-
IVWhydration
WhatWisWcausedWbyWacroleinW-WCORRECTWANSWERW-
aWtoxicWmetaboliteWofWcyclophosphamideWandWifofamideWthatWcanWcauseWhemorrhagicWcystitis
categoryWofWantineoplasticWdrugsWusedWanWalternativeWwhenWtraditionalWtreatmentsWfailW-
WCORRECTWANSWERW-
immunosuppressantsWactWasWanWalternativeWtreatmentWwhenWtraditionalWtreatmentsWfail
WhatWisWtopoisomeraseWinhibitorsWtargetWenzymesWthatWcontrolWchangesWinWDNAW-
WCORRECTWANSWERW-theyWtargetWenzymesWthatWcontrolWchangesWinWDNAWstructure
EffectsWdoWcholinesteraseWinhibitorsWhaveWonWtheWsinoatrialWandWatrioventricularWnodesW-
WCORRECTWANSWERW-VASOTONIC-
cholinesteraseWinhibitorsWhaveWeffectsWonWsinoatrialWandWatrioventricularWnodes
MechanismWofWactionWofW"mixedWacting"WsympathomimeticWdrugsW-WCORRECTWANSWERW-
theyWdirectlyWactivateWtheWreleaseWofWnorepinephrineWwhileWalsoWindirectlyWcausingWaWreleaseWo
fWnorepinephrine
IndicationWofWGABA-
derivativeWantispasmodicWagentsWinWtheWmanagementWandWcontrolWofWmuscleWspasmW-
WCORRECTWANSWERW-baclofen-
centrallyWactingWmuscleWrelaxant,WknownWtoWbeWmoreWeffectiveWwhenWusedWforWmuscularWspas
msWassociatedWwithWmultipleWsclerosisWcomparedWtoWthoseWthatWrelieveWotherWmusculoskeletalW
conditions